NCT04589390

Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Sao Paulo General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pulmonary arterial hypertension (PAH) is a severe, progressive and potentially fatal disease that impairs the pulmonary circulation and leads to right ventricular failure. One of the world most prevalent etiologies of PAH is schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH). New drugs have emerged to treat other forms of PAH, but their benefits cannot be automatically translated for Sch-PAH patients, since this etiology was not included in the pivotal PAH trials. One of the most promising therapies for the treatment of PAH to emerge in recent years is selexipag, an oral IP receptor agonist, which acts on the prostacyclin pathway. The present study aims to evaluate the efficacy, safety and tolerability of selexipague for the treatment of schistosomiasis-associated pulmonary arterial hypertension.

Conditions

• Pulmonary Hypertension
• Schistosomiasis

Interventions

Type	Name	Description
DRUG	Selexipag	treatment with selexipag

Timeline

• Start date: 2020-10-15
• Primary completion: 2021-11-30
• Completion: 2022-03-31
• First posted: 2020-10-19
• Last updated: 2020-10-19

Locations

1 site across 1 country: Brazil